Cxbladder Bulletin - March 2026
26th March 2026
Pacific Edge Invites you to read the March 2026 edition of our Cxbladder Bulletin clinician newsletter. Read More
Expert CAC Panel - Recording Now Available
11th March 2026
View a recording of the Feb 19 CAC meeting led by Novitas, the MAC with jurisdiction of Pacific Edge’s laboratory operations in Pennsylvania. CACs are typically convened ahead of developing new or substantially revised Medicare policy and the expert panel clearly endorsed the use of urine-based biomarkers in the evaluation of hematuria as medically reasonable and necessary. Read More
First Triage Plus Tests Ordered From Townsville
05th March 2026
Pacific Edge announces today that after 11 referrals for Cxbladder were sent to patients last week, the first Triage Plus test has now been ordered by Townsville University Hospital, Queensland, according to an agreed clinical pathway. Read More
Leading Singapore Hospital Now Ordering Cxbladder
03rd March 2026
Pacific Edge today announces its Dunedin laboratory has signed a service agreement with Singapore General Hospital (SGH), an important milestone in the company’s strategy to drive the adoption of its tests in the Asia Pacific. Read More
Expert Panel Expresses Clear Support for Urine-Based Biomarkers in Hematuria Evaluation
23rd February 2026
Pacific Edge today summarizes the opinions expressed by the panel of experts during the Contractor Advisory Committee (CAC) meeting organized by Novitas on Thursday 19 February 2026 (US time) regarding the use of urine-based biomarker tests in the evaluation of hematuria. Read More
Kaiser Study Backs Cxbladder Triage Ahead of Medicare Panel
27th January 2026
Pacific Edge welcomes the publication, in the journal 'Urology Practice', of a Kaiser Permanente study demonstrating the real-world Clinical Utility of Cxbladder Triage in the largest ever urine-based biomarker study on patients presenting with hematuria. Read More